Toxic Epidermal Neurolysis Market

Toxic Epidermal Neurolysis Market:Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030

Market Overview

Toxic epidermal necrolysis (TEN) is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis and/or death.

Mucous membrane involvement can result in gastrointestinal hemorrhage, respiratory failure, ocular abnormalities, and genitourinary complications.Based on drug class, the toxic epidermal market can be segmented into antibiotics, corticosteroids and immunoglobulins.

The antibiotic segment is expected to contribute considerable growth during the forecast period.The severity of toxic epidermal neurolysis is expected to contribute towards the market growth , although the disease is rare and has a lower frequency globally.

The outbreak of COVID-19 has appeared to have affected the toxic epidermal neurolysis market. The breakout of this disease has led to lockdowns across globe which has slowed down the growth in this market.

However, the market is expected to catch up and grow significantly in the forecast years.

Toxic Epidermal Neurolysis Market: Drivers and Restraints

To help in building preventive strategies, the move towards advanced non-invasive approaches for early diagnosis of toxic epidermal neurolysis is expected to boost the growth of the global toxic epidermal neurolysis market.

The growing consciousness about aesthetics may also contribute towards the growth of toxic epidermal neurolysis market.However, the low frequency of the disease may restrain the growth of toxic epidermal neurolysis market.

Toxic Epidermal Neurolysis Market: Overview

The global market for toxic epidermal neurolysis market is estimated to experience a significant growth due to the increasing demand for early diagnosis of the disease.Based on type, the global toxic epidermal neurolysis market is segmented into brain antibiotics, corticosteroids and immunoglobulins.

Antibiotics are expected to contribute considerable growth during the forecast period in the toxic epidermal neurolysis market. As antibiotics are prescribed to majority of the patients with toxic epidermal neurolysis to prevent or treat any infections.

However, immunoglobulins are also expected to contribute significant growth in the toxic epidermal neurolysis market during the forecast period.

Based on components the toxic epidermal neurolysis market may be divided into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies and retail pharmacies are expected to contribute the largest portion of revenue in the forecast years.

However, with the rapid changes in technology and growing acceptance of e-commerce by the people worldwide, it may lead to the growth of the online pharmacies in the forecast years.

Toxic Epidermal Neurolysis Market: Regional-Wise Outlook

Geographically, the toxic epidermal neurolysis market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa.

The North America is expected to account for the largest share in the toxic epidermal neurolysis market due to incidence of the disease which is highest in this region.

Europe is expected to have the largest share due to improving medical infrastructure.  However, East Asia is expected to observe a substantial growth in the toxic epidermal neurolysis market due to growing consciousness for aesthetics.

On the other hand, South Asia is anticipated to experience fastest growth in the toxic epidermal neurolysis market as a result of developing medical infrastructure.

In the Middle East and Africa the market is expected to experience limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.

Toxic Epidermal Neurolysis Market: Key players

Some of the players identified in the toxic epidermal neurolysis market include:

  • Pfizer
  • Novartis
  • Sanofi
  • Merck and Co
  • Sun pharma
  • Abbott laboratories
  • Johnson & Johnson
  • Teva pharmaceuticals
  • Mylan pharmaceuticals

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology Matrix
  • Value Chain

Regional analysis of the toxic epidermal neurolysis market report includes

  • North America
  • Latin America
  • Europe
  • South  Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Toxic Epidermal Neurolysis market Report Highlights:

  • Overview of Global Healthcare Market
  • Evolution of the technology
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

Toxic Epidermal Neurolysis Market: Segmentation

Tentatively, the global toxic epidermal neurolysis market has been segmented on the basis of drug class and distribution channel.

By drug class:

  • Antibiotics
  • Corticosteroids
  • Intravenous immunoglobulins

By distribution channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Toxic Epidermal Neurolysis Market